Patents by Inventor Laurence Fayadat-Dilman
Laurence Fayadat-Dilman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11045547Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.Type: GrantFiled: December 13, 2016Date of Patent: June 29, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Rene De Waal Malefyt, Laurence Fayadat-Dilman, Linda Liang
-
Publication number: 20210032342Abstract: The present invention relates to anti-PD-1 antibodies and antigen-binding fragments, and use of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.Type: ApplicationFiled: January 31, 2019Publication date: February 4, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Laurence FAYADAT-DILMAN, Veronica JUAN, Shireen KHAN, Shaopeng HUANG, Hua YING
-
Patent number: 10898571Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.Type: GrantFiled: December 4, 2018Date of Patent: January 26, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Linda Liang, Laurence Fayadat-Dilman, Rene De Waal Malefyt, Gopalan Raghunathan
-
Publication number: 20210017276Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: ApplicationFiled: July 27, 2020Publication date: January 21, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Sybil M.G. Williams, Wolfgang Seghezzi, Laurence Fayadat-Dilman, Linda Liang, Veronica Juan
-
Patent number: 10766957Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: GrantFiled: August 9, 2016Date of Patent: September 8, 2020Assignee: MERCK SHARP & DOHME CORPInventors: Sybil M. G. Williams, Wolfgang Seghezzi, Laurence Fayadat-Dilman, Linda Liang, Veronica Juan
-
Publication number: 20200270346Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: ApplicationFiled: May 15, 2020Publication date: August 27, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Sybil M. G. Williams, Drake LaFace, Laurence Fayadat-Dilman, Gopalan Raghunathan, Linda Liang, Wolfgang Seghezzi
-
Publication number: 20200131272Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: ApplicationFiled: December 23, 2019Publication date: April 30, 2020Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
-
Patent number: 10618958Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: GrantFiled: November 20, 2017Date of Patent: April 14, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Sybil M. G. Williams, Drake LaFace, Laurence Fayadat-Dilman, Gopalan Raghunathan, Linda Liang, Wolfgang Seghezzi
-
Patent number: 10556957Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: GrantFiled: September 25, 2017Date of Patent: February 11, 2020Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B. V.Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
-
Publication number: 20190300618Abstract: The present invention relates to anti-CD27 antibodies, as well as use antibodies in the treatment of diseases such as cancer and infectious disease.Type: ApplicationFiled: September 25, 2017Publication date: October 3, 2019Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
-
Publication number: 20190233518Abstract: Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.Type: ApplicationFiled: January 31, 2019Publication date: August 1, 2019Inventors: Laurence Fayadat-Dilman, Veronica Juan, Shireen Khan, Shaopeng Huang, Hua Ying, Eric Escobar Cabrera, Genevieve Desjardins
-
Publication number: 20190153093Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.Type: ApplicationFiled: November 15, 2018Publication date: May 23, 2019Applicant: MERCK SHARP & DOHME CORP.Inventors: MICHAEL A. MEEHL, PHILIP E. BRANDISH, LAURENCE FAYADAT-DILMAN, VERONICA JUAN, CARL MIECZKOWSKI, LATIKA SINGH
-
Publication number: 20190091332Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.Type: ApplicationFiled: December 7, 2018Publication date: March 28, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Linda Liang, Laurence Fayadat-Dilman, Rene De Waal Malefyt, Gopalan Raghunathan
-
Publication number: 20190083614Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.Type: ApplicationFiled: December 4, 2018Publication date: March 21, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Linda Liang, Laurence Fayadat-Dilman, Rene De Waal Malefyt, Gopalan Raghunathan
-
Publication number: 20190083615Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.Type: ApplicationFiled: December 5, 2018Publication date: March 21, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Linda Liang, Laurence Fayadat-Dilman, Rene De Waal Malefyt, Gopalan Raghunathan
-
Patent number: 10188730Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAGS as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.Type: GrantFiled: April 7, 2017Date of Patent: January 29, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Linda Liang, Laurence Fayadat-Dilman, Rene De Waal Malefyt, Gopalan Raghunathan
-
Publication number: 20180369375Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.Type: ApplicationFiled: December 13, 2016Publication date: December 27, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Rene De Waal Malefyt, Laurence Fayadat-Dilman, Linda Liang
-
Publication number: 20180371083Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: ApplicationFiled: August 9, 2016Publication date: December 27, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Sybil M.G. Williams, Wolfgang Seghezzi, Laurence Fayadat-Dilman, Linda Liang, Veronica Juan
-
Publication number: 20180086841Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: ApplicationFiled: September 25, 2017Publication date: March 29, 2018Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
-
Publication number: 20180066055Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: ApplicationFiled: November 20, 2017Publication date: March 8, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Sybil M. G. Williams, Drake LaFace, Laurence Fayadat-Dilman, Gopalan Raghunathan, Linda Liang, Wolfgang Seghezzi